Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum

References

• Ahmed A, Dunk C, Ahmad S, Khaliq A. 2000. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen–a review. Placenta 21:S16–S24.
   PubMed Web of Science ®Google Scholar
• Bartels H, Postle JD, Downey P, Brennan DJ. 2018. Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Disease Markers 2018:1507674.
   PubMed Web of Science ®Google Scholar
• Belfort MA. 2010. Placenta accreta. American Journal of Obstetrics and Gynecology 203:430–439.
   PubMed Web of Science ®Google Scholar
• Belfort MA, Shamshirsaz AA, Fox KA. 2018. The diagnosis and management of morbidly adherent placenta. Seminars in Perinatology 42:49–58.
   PubMed Web of Science ®Google Scholar
• Berkley EM, Abuhamad A. 2018. Imaging of placenta accreta spectrum. Clinical Obstetrics and Gynecology 61:755–765.
   PubMed Web of Science ®Google Scholar
• Biberoglu E, Kirbas A, Daglar K, Biberoglu K, Timur H, Demirtas C, et al. 2016. Serum angiogenic profile in abnormal placentation. The Journal of Maternal-Fetal & Neonatal Medicine 29:3193–3197.
   PubMed Web of Science ®Google Scholar
• Burton GJ, Woods AW, Jauniaux E, Kingdom JC. 2009. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 30:473–482.
   PubMed Web of Science ®Google Scholar
• Dannheim K, Shainker SA, Hecht JL. 2016. Hysterectomy for placenta accreta; methods for gross and microscopic pathology examination. Archives of Gynecology and Obstetrics 293:951–958.
   PubMed Web of Science ®Google Scholar
• El Gelany S, Mosbeh MH, Ibrahim EM, Mohammed M, Khalifa EM, Abdelhakium AK, et al. 2019. Placenta Accreta Spectrum (PAS) disorders: incidence, risk factors and outcomes of different management strategies in a tertiary referral hospital in Minia, Egypt: a prospective study. BMC Pregnancy and Childbirth 19:313.
   PubMed Web of Science ®Google Scholar
• Farquhar CM, Li Z, Lensen S, Mclintock C, Pollock W, Peek MJ, et al. 2017. Incidence, risk factors and perinatal outcomes for placenta accreta in Australia and New Zealand: a case-control study. BMJ Open 7:e017713.
   PubMed Web of Science ®Google Scholar
• Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. 2000. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Laboratory Investigation 80:443–454.
   PubMed Web of Science ®Google Scholar
• Hull AD, Moore TR. 2011. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management. Clinics in Perinatology 38:285–296.
   PubMed Web of Science ®Google Scholar
• Jauniaux E, Bunce C, Grønbeck L, Langhoff-Roos J. 2019. Prevalence and main outcomes of placenta accreta spectrum: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology 221:208–218.
   PubMed Web of Science ®Google Scholar
• Jauniaux E, Burton GJ. 2018. Pathophysiology of placenta accreta spectrum disorders: a review of current findings. Clinical Obstetrics and Gynecology 61:743–754.
   PubMed Web of Science ®Google Scholar
• Jauniaux E, Collins S, Burton GJ. 2018. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging . American Journal of Obstetrics and Gynecology 218:75–87.
   PubMed Web of Science ®Google Scholar
• Jauniaux E, Jurkovic D. 2012. Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease. Placenta 33:244–251.
   PubMed Web of Science ®Google Scholar
• Khong TY. 2008. The pathology of placenta accreta, a worldwide epidemic. Journal of Clinical Pathology 61:1243–1246.
   PubMed Web of Science ®Google Scholar
• Korkmazer E, Nizam R, Arslan E, Akkurt Ö. 2018. Relationship between intercellular adhesion molecule-1 and morbidly adherent placenta. Journal of Perinatal Medicine 47:45–49.
   PubMed Web of Science ®Google Scholar
• Kyozuka H, Yamaguchi A, Suzuki D, Fujimori K, Hosoya M, Yasumura S, et al. 2019. Risk factors for placenta accreta spectrum: findings from the Japan environment and Children's study. BMC Pregnancy and Childbirth 19:447.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. The Journal of Clinical Investigation 111:649–658.
   PubMed Web of Science ®Google Scholar
• Öztaş E, Özler S, Ergin M, Erel Ö, Gümüş Güler B, Çağlar AT, et al. 2017. Decreased oxidative stress may contribute to the disease process in placenta accreta. Turkish Journal of Medical Sciences 47:1180–1184.
   PubMed Web of Science ®Google Scholar
• Oztas E, Ozler S, Ersoy AO, Ersoy E, Caglar AT, Uygur D, et al. 2016. Decreased placental and maternal serum TRAIL-R2 levels are associated with placenta accreta. Placenta 39:1–6.
   PubMed Web of Science ®Google Scholar
• Setudezadeh F. 2018. YT: The increasing prevalence of cesarean in Iran: how the rate of cesareans could be controlled. Obstetrics and Gynecology International Journal 9:532–535.
   Google Scholar
• Shainker SA, Dannheim K, Gerson KD, Neo D, Zsengeller ZK, Pernicone E, et al. 2017. Down-regulation of soluble fms-like tyrosine kinase 1 expression in invasive placentation. Archives of Gynecology and Obstetrics 296:257–262.
   PubMed Web of Science ®Google Scholar
• Shamshirsaz AA, Fox KA, Erfani H, Clark SL, Shamshirsaz AA, Nassr AA, et al. 2018. Outcomes of planned compared with urgent deliveries using a multidisciplinary team approach for morbidly adherent placenta. Obstetrics & Gynecology 131:234–241.
   PubMed Web of Science ®Google Scholar
• Shibuya M. 2011. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes & Cancer 2:1097–1105.
   PubMedGoogle Scholar
• Shirakawa T, Miyahara Y, Tanimura K, Morita H, Kawakami F, Itoh T, et al. 2015. Expression of epithelial-mesenchymal transition-related factors in adherent placenta. International Journal of Gynecological Pathology 34:584–589.
   PubMed Web of Science ®Google Scholar
• Silver RM, Barbour KD. 2015. Placenta accreta spectrum: accreta, increta, and percreta. Obstetrics and Gynecology Clinics of North America 42:381–402.
   PubMed Web of Science ®Google Scholar
• Tseng JJ, Chou MM. 2006. Differential expression of growth-, angiogenesis- and invasion-related factors in the development of placenta accreta. Taiwanese Journal of Obstetrics & Gynecology 45:100–106.
   PubMedGoogle Scholar
• Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL. 2006. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 27:70–78.
   PubMed Web of Science ®Google Scholar
• Uyanıkoğlu H, İncebıyık A, Turp AB, Çakmak G, Sak S, Hilali NG. 2018. Serum angiogenic and anti-angiogenic markers in pregnant women with placenta percreta. Balkan Medical Journal 35:55–60.
   PubMed Web of Science ®Google Scholar
• Wehrum MJ, Buhimschi IA, Salafia C, Thung S, Bahtiyar MO, Werner EF, et al. 2011. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. American Journal of Obstetrics and Gynecology 204:411.e1–411.e11.
   PubMed Web of Science ®Google Scholar